Inmed issues annual letter to shareholders highlighting key accomplishments from 2021 and providing 2022 outlook

Vancouver, british columbia, jan. 05, 2022 (globe newswire) -- inmed pharmaceuticals inc. (“inmed” or the “company”) (nasdaq: inm), a leader in the development, manufacturing and commercialization of rare cannabinoids, today issued the following letter from president and ceo eric a. adams.

INM Ratings Summary

INM Quant Ranking